FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4286293818> ?p ?o ?g. }

• W4286293818 endingPage "4581" @default.
• W4286293818 startingPage "4581" @default.
• W4286293818 abstract "4581 Background: SWOG S1314 (NCT02177695) was designed to validate the CoXEN classifier as a predictive biomarker in pts undergoing cystectomy after NAC. We repurposed banked DNA samples and prospective trial data from S1314 to further validate the predictive ability of the Philadelphia 4 gene signature (P4GS: any mutation in ATM, RB1, FANCC, ERCC2) to predict pT0 as previously reported (PMID: 26238431) and used in the RETAIN trial (NCT02710734). The RETAIN trial prospectively enrolled pts to receive NAC (DDMVAC) followed by allocation to bladder observation vs. intervention (cystectomy or RT) based on clinical evaluation and presence vs absence of P4GS. The primary objective of this correlative investigation was to determine whether presence of P4GS is predictive of pT0 at surgery. Methods: Eligibility for S1314 included cT2-T4a N0 M0 MIBC, cisplatin eligible, with plan for cystectomy; 237 pts were randomized between ddMVAC and gem/cis (GC) using standard dose/schedule. Of 167 pts who were evaluable for the original COXEN analysis (received 3+ cycles of chemo and evaluable for path response) adequate banked DNA was available for 105. Next-generation sequencing using the CARIS 592 Gene Panel (Caris Life Sciences, Phoenix, AZ) was performed. Pathogenic mutation or VUS of ATM, RB1, FANCC or ERCC2 was noted as present or absent for each pt and correlated with pT0 using logistic regression, adjusting for clinical stage. Results: Among the 105 pts, 51% ddMVAC, 49% GC. 15% female, 95% white, 15% clinical stage T3/T4a Prevalence of mutations: ATM (24%), ERCC2 (17%), FANCC (4%), RB1 (24%) and any variant 53%. Presence of any mutation correlated with pT0 (p = 0.0006), sensitivity 79%, specificity 59%. This association did not vary by treatment arm (MVAC vs. GC). The table below shows the contributions of each of the 4 genes with the greatest contribution from ATM and ERCC2. FANCC was non-contributory due to low prevalence. Conclusions: Patients with a mutation in ATM, RB1, FANCC or ERCC2 (P4GS) have a statistically significantly higher odds of a pT0 with GC or MVAC compared to those who do not have any variant. This signature was used to prospectively allocate patients to bladder observation as part of the RETAIN trial previously reported (ASCO GU 2021). RETAIN completed enrollment, final analysis of the primary endpoint – 2-year metastasis free survival – is expected later in 2022. Clinical trial information: NCT02177695." @default.
• W4286293818 created "2022-07-21" @default.
• W4286293818 creator A5002737792 @default.
• W4286293818 creator A5005711087 @default.
• W4286293818 creator A5026563364 @default.
• W4286293818 creator A5032422193 @default.
• W4286293818 creator A5033183688 @default.
• W4286293818 creator A5033555611 @default.
• W4286293818 creator A5037573167 @default.
• W4286293818 creator A5041043417 @default.
• W4286293818 creator A5048218662 @default.
• W4286293818 creator A5051857189 @default.
• W4286293818 creator A5059536506 @default.
• W4286293818 creator A5076568375 @default.
• W4286293818 creator A5080544645 @default.
• W4286293818 creator A5088312939 @default.
• W4286293818 date "2022-06-01" @default.
• W4286293818 modified "2023-10-12" @default.
• W4286293818 title "S1314 correlative analysis of ATM, RB1, ERCC2, and FANCC mutations and pathologic complete response (pT0) at cystectomy after neoadjuvant chemotherapy (NAC) in patients with muscle invasive bladder cancer (MIBC): Implications for bladder preservation." @default.
• W4286293818 doi "https://doi.org/10.1200/jco.2022.40.16_suppl.4581" @default.
• W4286293818 hasPublicationYear "2022" @default.
• W4286293818 type Work @default.
• W4286293818 citedByCount "3" @default.
• W4286293818 countsByYear W42862938182023 @default.
• W4286293818 crossrefType "journal-article" @default.
• W4286293818 hasAuthorship W4286293818A5002737792 @default.
• W4286293818 hasAuthorship W4286293818A5005711087 @default.
• W4286293818 hasAuthorship W4286293818A5026563364 @default.
• W4286293818 hasAuthorship W4286293818A5032422193 @default.
• W4286293818 hasAuthorship W4286293818A5033183688 @default.
• W4286293818 hasAuthorship W4286293818A5033555611 @default.
• W4286293818 hasAuthorship W4286293818A5037573167 @default.
• W4286293818 hasAuthorship W4286293818A5041043417 @default.
• W4286293818 hasAuthorship W4286293818A5048218662 @default.
• W4286293818 hasAuthorship W4286293818A5051857189 @default.
• W4286293818 hasAuthorship W4286293818A5059536506 @default.
• W4286293818 hasAuthorship W4286293818A5076568375 @default.
• W4286293818 hasAuthorship W4286293818A5080544645 @default.
• W4286293818 hasAuthorship W4286293818A5088312939 @default.
• W4286293818 hasConcept C104317684 @default.
• W4286293818 hasConcept C121608353 @default.
• W4286293818 hasConcept C126322002 @default.
• W4286293818 hasConcept C135763542 @default.
• W4286293818 hasConcept C143998085 @default.
• W4286293818 hasConcept C146357865 @default.
• W4286293818 hasConcept C151730666 @default.
• W4286293818 hasConcept C153209595 @default.
• W4286293818 hasConcept C2775910329 @default.
• W4286293818 hasConcept C2778883343 @default.
• W4286293818 hasConcept C2780352672 @default.
• W4286293818 hasConcept C55493867 @default.
• W4286293818 hasConcept C71924100 @default.
• W4286293818 hasConcept C86803240 @default.
• W4286293818 hasConceptScore W4286293818C104317684 @default.
• W4286293818 hasConceptScore W4286293818C121608353 @default.
• W4286293818 hasConceptScore W4286293818C126322002 @default.
• W4286293818 hasConceptScore W4286293818C135763542 @default.
• W4286293818 hasConceptScore W4286293818C143998085 @default.
• W4286293818 hasConceptScore W4286293818C146357865 @default.
• W4286293818 hasConceptScore W4286293818C151730666 @default.
• W4286293818 hasConceptScore W4286293818C153209595 @default.
• W4286293818 hasConceptScore W4286293818C2775910329 @default.
• W4286293818 hasConceptScore W4286293818C2778883343 @default.
• W4286293818 hasConceptScore W4286293818C2780352672 @default.
• W4286293818 hasConceptScore W4286293818C55493867 @default.
• W4286293818 hasConceptScore W4286293818C71924100 @default.
• W4286293818 hasConceptScore W4286293818C86803240 @default.
• W4286293818 hasFunder F4320332161 @default.
• W4286293818 hasIssue "16_suppl" @default.
• W4286293818 hasLocation W42862938181 @default.
• W4286293818 hasOpenAccess W4286293818 @default.
• W4286293818 hasPrimaryLocation W42862938181 @default.
• W4286293818 hasRelatedWork W123182686 @default.
• W4286293818 hasRelatedWork W2009115226 @default.
• W4286293818 hasRelatedWork W2044302646 @default.
• W4286293818 hasRelatedWork W2122063636 @default.
• W4286293818 hasRelatedWork W2789722324 @default.
• W4286293818 hasRelatedWork W2915528798 @default.
• W4286293818 hasRelatedWork W2946011640 @default.
• W4286293818 hasRelatedWork W3049739686 @default.
• W4286293818 hasRelatedWork W3202848091 @default.
• W4286293818 hasRelatedWork W4232716117 @default.
• W4286293818 hasVolume "40" @default.
• W4286293818 isParatext "false" @default.
• W4286293818 isRetracted "false" @default.
• W4286293818 workType "article" @default.